{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:48:02Z","timestamp":1792414082444,"version":"4.4.0"},"reference-count":37,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"10","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2026,10,19]]},"DOI":"10.1167\/tvst.15.10.27","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:30:49Z","timestamp":1792413049000},"page":"27","source":"Crossref","is-referenced-by-count":0,"title":["Protection of Bevacizumab From Silicone Oil\u2013Induced Inactivation by Liposomal Encapsulation"],"prefix":"10.1167","volume":"15","author":[{"given":"Sabrina","family":"Wohlfart","sequence":"first","affiliation":[{"name":"David J Apple Laboratory for Vision Research, University Eye Clinic Heidelberg, Heidelberg, Germany"},{"name":"Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Junker","sequence":"additional","affiliation":[{"name":"David J Apple Laboratory for Vision Research, University Eye Clinic Heidelberg, Heidelberg, Germany"},{"name":"Department of Ophthalmology, University Clinic Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hellen Gertrud","family":"R\u00f6ttgen","sequence":"additional","affiliation":[{"name":"David J Apple Laboratory for Vision Research, University Eye Clinic Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Ben","family":"B\u00f6hmann","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Aristide","family":"Augustin","sequence":"additional","affiliation":[{"name":"David J Apple Laboratory for Vision Research, University Eye Clinic Heidelberg, Heidelberg, Germany"},{"name":"Department of Ophthalmology, University Clinic Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd Uwe","family":"Auffarth","sequence":"additional","affiliation":[{"name":"David J Apple Laboratory for Vision Research, University Eye Clinic Heidelberg, Heidelberg, Germany"},{"name":"Department of Ophthalmology, University Clinic Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Uhl","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Hammer","sequence":"additional","affiliation":[{"name":"David J Apple Laboratory for Vision Research, University Eye Clinic Heidelberg, Heidelberg, Germany"},{"name":"Department of Ophthalmology, University Clinic Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"issue":"8","key":"bib1","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/ph16081140","article-title":"Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders","volume":"16","author":"Hang","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"2","key":"bib2","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","article-title":"A brief history of anti-VEGF for the treatment of ocular angiogenesis","volume":"181","author":"Kim","year":"2012","journal-title":"Am J Pathol"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1001\/archopht.1962.00960030594005","article-title":"The use of liquid silicone in retinal detachment surgery","volume":"68","author":"Cibis","year":"1962","journal-title":"Arch Ophthalmol"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/archopht.1962.00960030394013","article-title":"Ocular tolerance to silicones. I. Replacement of aqueous and vitreous by silicone fluids","volume":"68","author":"Armaly","year":"1962","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"bib5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0002-9394(85)90788-3","article-title":"Temporary silicone oil tamponade in the management of retinal detachment with proliferative vitreoretinopathy","volume":"100","author":"Gonvers","year":"1985","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"bib6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00417-011-1873-8","article-title":"Retrospective review of 50 eyes with long-term silicone oil tamponade for more than 12 months","volume":"250","author":"Morphis","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"bib7","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1097\/IAE.0000000000003432","article-title":"The novel use of high-flow polyimide cannulas to improve silicone oil injectability in vitreoretinal surgery","volume":"42","author":"Hammer","year":"2022","journal-title":"Retina"},{"issue":"1","key":"bib8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40942-023-00481-w","article-title":"New approaches to explanting high-viscosity silicone oil in retinal surgery\u2014polyimide cannulas vs extraction sleeves vs a luer-trocar","volume":"9","author":"Hammer","year":"2023","journal-title":"Int J Retina Vitreous"},{"issue":"2","key":"bib9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/tvst.11.2.3","article-title":"Physicochemical Properties of explanted silicone oil after use as an intraocular tamponade","volume":"11","author":"Hammer","year":"2022","journal-title":"Transl Vis Sci Technol"},{"issue":"7","key":"bib10","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3390\/pharmaceutics14071364","article-title":"Intravitreal application: physicochemical properties of drugs dissolved in silicone oils of different density in comparison to the porcine vitreous body","volume":"14","author":"Hammer","year":"2022","journal-title":"Pharmaceutics"},{"issue":"13","key":"bib11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1167\/iovs.65.13.56","article-title":"Exposure to silicone oil endotamponades induces VEGF antibody aggregation and loss of functionality","volume":"65","author":"Wohlfart","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"132409","DOI":"10.1016\/j.cej.2021.132409","article-title":"Therapeutic hydrogel sheets programmed with multistage drug delivery for effective treatment of corneal abrasion","volume":"429","author":"Luo","year":"2022","journal-title":"Chem Eng J"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"101634","DOI":"10.1016\/j.pmatsci.2025.101634","article-title":"Hollow nanoarchitectures: materials engineering, nanochemistry, and biomedical applications","volume":"158","author":"Ghosh","year":"2026","journal-title":"Prog Mater Sci"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"101875","DOI":"10.1016\/j.cocis.2024.101875","article-title":"Liposomes: bridging the gap from lab to pharmaceuticals","volume":"75","author":"Eugster","year":"2025","journal-title":"Curr Opin Colloid Interface Sci"},{"issue":"2","key":"bib15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal formulations in clinical use: an updated review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"863734","DOI":"10.1155\/2011\/863734","article-title":"Recent applications of liposomes in ophthalmic drug delivery","volume":"2011","author":"Mishra","year":"2011","journal-title":"J Drug Deliv"},{"issue":"9","key":"bib17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1089\/jop.2017.0052","article-title":"Relevance of lipid-based products in the management of dry eye disease","volume":"33","author":"Garrigue","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"bib18","doi-asserted-by":"publisher","first-page":"e03230","DOI":"10.1002\/adhm.202503230","article-title":"Methotrexate-loaded liposomal formulation enables 6-week sustained intraocular therapeutic drug release in a porcine model","volume":"15","author":"Hammer","year":"2026","journal-title":"Adv Healthc Mater"},{"issue":"6","key":"bib19","first-page":"1523","article-title":"Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation","volume":"41","author":"Cheng","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"bib20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/IAE.0b013e3181a2f42a","article-title":"Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration","volume":"29","author":"Abrishami","year":"2009","journal-title":"Retina"},{"issue":"8","key":"bib21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/gels10080501","article-title":"In vitro physicochemical and pharmacokinetic properties of bevacizumab dissolved in silicone oils compared to hydrogel-substitutes and porcine vitreous bodies","volume":"10","author":"Hammer","year":"2024","journal-title":"Gels"},{"issue":"8","key":"bib22","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1021\/acs.analchem.5b00140","article-title":"Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles","volume":"87","author":"Marty","year":"2015","journal-title":"Anal Chem"},{"issue":"8","key":"bib23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s11095-018-2430-5","article-title":"Considerations for the use of polysorbates in biopharmaceuticals","volume":"35","author":"Jones","year":"2018","journal-title":"Pharm Res"},{"issue":"7","key":"bib24","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1167\/iovs.09-4373","article-title":"Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes","volume":"51","author":"Zhang","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"bib25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1089\/jop.2000.16.511","article-title":"Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes","volume":"16","author":"Gupta","year":"2000","journal-title":"J Ocul Pharmacol Ther"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"123958","DOI":"10.1016\/j.ijpharm.2024.123958","article-title":"Design of liposomal nanocarriers with a potential for combined dexamethasone and bevacizumab delivery to the eye","volume":"654","author":"Farooq","year":"2024","journal-title":"Int J Pharmaceut"},{"issue":"11","key":"bib27","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1002\/nano.70010","article-title":"Liposomes containing tetraether lipids and cell-penetrating peptides as platform technology for oral delivery of peptides: a comparative study on GLP-1 analogs","volume":"6","author":"Herbster","year":"2025","journal-title":"Nano Select"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.carbon.2022.09.045","article-title":"Anti-angiogenic carbon nanovesicles loaded with bevacizumab for the treatment of age-related macular degeneration","volume":"201","author":"Anand","year":"2023","journal-title":"Carbon"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"101156","DOI":"10.1016\/j.apmt.2021.101156","article-title":"Targeting nanocomposites with anti-oxidative\/inflammatory\/angiogenic activities for synergistically alleviating macular degeneration","volume":"24","author":"Luo","year":"2021","journal-title":"Appl Mater Today"},{"issue":"1","key":"bib30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1021\/acsnano.2c05824","article-title":"Highly retina-permeating and long-acting resveratrol\/metformin nanotherapeutics for enhanced treatment of macular degeneration","volume":"17","author":"Nguyen","year":"2023","journal-title":"ACS Nano"},{"issue":"4","key":"bib31","first-page":"235","article-title":"Anti-vascular endothelial growth factor indications in ocular disease","volume":"59","author":"Cornel","year":"2015","journal-title":"Rom J Ophthalmol"},{"issue":"3","key":"bib32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ophtha.2013.07.015","article-title":"United Kingdom National Ophthalmology Database study of vitreoretinal surgery: Report 3, Retinal Detachment","volume":"121","author":"Jackson","year":"2014","journal-title":"Ophthalmology"},{"issue":"5","key":"bib33","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/eye.2014.13","article-title":"A review of anti-VEGF agents for proliferative diabetic retinopathy","volume":"28","author":"Osaadon","year":"2014","journal-title":"Eye (Lond)"},{"issue":"13","key":"bib34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Diabetic Retinopathy Clinical Research Network","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"bib35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11892-021-01396-2","article-title":"Management of complications and vision loss from proliferative diabetic retinopathy","volume":"21","author":"Crabtree","year":"2021","journal-title":"Curr Diab Rep"},{"issue":"10","key":"bib36","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s00417-019-04414-y","article-title":"Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage","volume":"257","author":"Angermann","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"bib37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1167\/iovs.67.8.36","article-title":"Vitrectomy status alters early intravitreal drug distribution: an ex vivo PET-CT study","volume":"67","author":"Wohlfart","year":"2026","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/tvst.arvojournals.org\/article.aspx?doi=10.1167\/tvst.15.10.27","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:30:50Z","timestamp":1792413050000},"score":1,"resource":{"primary":{"URL":"http:\/\/tvst.arvojournals.org\/article.aspx?doi=10.1167\/tvst.15.10.27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.15.10.27","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,19]]}}}